Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rutherford

Showing results (581-590 of 603) with videos related to

Pageof 61
Sort By:
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
International Journal of Cancer|June 11, 2015
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerEmiliano Cocco, Erik M Shapiro, Sara Gasparrini, et al.
Gut|June 20, 2020
International trends in oesophageal cancer survival by histological subtype between 1995 and 2014Eileen Morgan, Isabelle Soerjomataram, Anna T Gavin, et al.
Gut|June 3, 2020
Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)Marzieh Araghi, Melina Arnold, Mark J Rutherford, et al.
British Journal of Cancer|June 29, 2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapyS Bellone, R Tassi, M Betti, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 9, 2012
Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansionBaber K Khan, Jennifer S Yokoyama, Leonel T Takada, et al.
Human Molecular Genetics|August 30, 2008
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementiaRosa Rademakers, Jason L Eriksen, Matt Baker, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|September 1, 1996
AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study GroupM V Ragni, S H Belle, R Jaffe, et al.
Gut|November 26, 2021
International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)Melina Arnold, Eileen Morgan, Aude Bardot, et al.
Pageof 61

Showing results (581-590 of 603) with videos related to

Sort By:
Pageof 61
Gynecologic Oncology|February 14, 2017
Factors associated with deciding between risk-reducing salpingo-oophorectomy and ovarian cancer screening among high-risk women enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group studyPhuong L Mai, Marion Piedmonte, Paul K Han, et al.
International Journal of Cancer|June 11, 2015
Clostridium perfringens enterotoxin C-terminal domain labeled to fluorescent dyes for in vivo visualization of micrometastatic chemotherapy-resistant ovarian cancerEmiliano Cocco, Erik M Shapiro, Sara Gasparrini, et al.
Gut|June 20, 2020
International trends in oesophageal cancer survival by histological subtype between 1995 and 2014Eileen Morgan, Isabelle Soerjomataram, Anna T Gavin, et al.
Gut|June 3, 2020
Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project)Marzieh Araghi, Melina Arnold, Mark J Rutherford, et al.
British Journal of Cancer|June 29, 2013
Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapyS Bellone, R Tassi, M Betti, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 9, 2012
Atypical, slowly progressive behavioural variant frontotemporal dementia associated with C9ORF72 hexanucleotide expansionBaber K Khan, Jennifer S Yokoyama, Leonel T Takada, et al.
Human Molecular Genetics|August 30, 2008
Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementiaRosa Rademakers, Jason L Eriksen, Matt Baker, et al.
Oncogene|December 6, 2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancerE S Ratner, F K Keane, R Lindner, et al.
Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology : Official Publication of the International Retrovirology Association|September 1, 1996
AIDS-associated non-Hodgkin's lymphomas as primary and secondary AIDS diagnoses in hemophiliacs. Hemophilia Malignancy Study GroupM V Ragni, S H Belle, R Jaffe, et al.
Gut|November 26, 2021
International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study)Melina Arnold, Eileen Morgan, Aude Bardot, et al.
Pageof 61